After Shake-up, Sequenom Begins Designing Assays | GenomeWeb

After an aborted flirtation with drug discovery and a brush with the specter of downgraded stock, Sequenom is looking for a way up and out.

Two days after CEO Toni Schuh reiterated to investors his plan to set the company on track to profitability — a move that scuttled the company’s nascent pharmaceuticals business and will cost 50 staffers their jobs by the end of the year — the San Diego-based company this week introduced what it hopes will become a new source of revenue: an assay design service.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.